| dc.contributor.author | Ng, T | en_US |
| dc.contributor.author | Flores-Borja, F | en_US |
| dc.contributor.author | Alfano, G | en_US |
| dc.contributor.author | Barber, P | en_US |
| dc.contributor.author | Weitsman, G | en_US |
| dc.contributor.author | Wong, F | en_US |
| dc.contributor.author | Vicencio, J | en_US |
| dc.contributor.author | Galazi, M | en_US |
| dc.contributor.author | Doyle, J | en_US |
| dc.contributor.author | Greenberg, J | en_US |
| dc.contributor.author | Forster, MD | en_US |
| dc.contributor.author | Coolen, A | en_US |
| dc.date.accessioned | 2020-04-30T14:28:53Z | |
| dc.date.available | 2018-02-02 | en_US |
| dc.date.issued | 2018-05-20 | en_US |
| dc.identifier.issn | 0732-183X | en_US |
| dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/63866 | |
| dc.language.iso | en | en_US |
| dc.title | The use of exosome and immune profiling to analyze a phase 2 study on the addition of patritumab or placebo to cetuximab and a platinum agent for recurrent / metastatic head and neck cancer (R/M HNSCC) patients. | en_US |
| dc.type | Conference Proceeding | |
| dc.rights.holder | 2018 by American Society of Clinical Oncology | |
| dc.identifier.doi | 10.1200/JCO.2018.36.15_suppl.6043 | en_US |
| pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000442916002333&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
| pubs.issue | 15 | en_US |
| pubs.notes | Not known | en_US |
| pubs.publication-status | Published | en_US |
| pubs.volume | 36 | en_US |
| rioxxterms.funder | Default funder | en_US |
| rioxxterms.identifier.project | Default project | en_US |
